Stocks
Intensity Therapeutics, Inc.INTS
NASDAQHealthcareBiotechnology$3.25
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing intratumoral cancer immunotherapies, with its lead candidate INT230-6 in Phase 3 trials for soft tissue sarcoma. Investors track the stock for its potential in a niche oncology space, though clinical readouts and regulatory milestones drive volatility.
52W Range: $3.09-$43.50
Congressional Interest in Intensity Therapeutics, Inc. (INTS)
No congressional trades have been disclosed for Intensity Therapeutics, Inc. (INTS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading INTS?
No congressional trades found for this stock.